Recent Updates
Recently added Catalysts
INO Positive Sentiment

INOVIO to Participate in Upcoming Scientific Conference

Wednesday, April 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: INOVIO (NASDAQ:INO) has announced its participation in the World Federation of Hemophilia World Congress in Kuala Lumpur. The company will present on its DNA-Encoded Protein (DPROT) technology and its non-viral vector DNA medicine platform for hemophilia A. Abstracts will be available on INOVIO's website after the presentations.
Price reaction · baseline $1.74 (2026-03-31 close) · hit after-hours · 2 other INO headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is actively participating in a significant scientific conference.
  • The presentations will showcase innovative DNA medicine technologies.
  • The company continues to advance its research in treating hemophilia A.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
VGX-410
Phase 2 · Hepatitis C Virus Infection

Full Press Release Details

PLYMOUTH MEETING, Pa.,April 1, 2026/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conference:

World Federation of Hemophilia World Congress(Kuala Lumpur)

• Presentation:Next Gen Protein Replacement Therapeutics: DNA-Encoded Protein (DPROT) Technology Demonstrates in vivo Production of Functional FVIII in Mouse ModelDate:Wednesday, April 22Time:9:45 AM MYT
• Poster Presentation:FVIII Expression Via Non-viral Vector DNA Medicine Platform Results in Efficacious Levels of FVIII Protein and Correction of the Bleeding Phenotype in Hemophilia A MiceDate:Wednesday, April 22Time: 10:45 AM MYT
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visitwww.inovio.com.

ContactsMedia: Jennie Willson, (267) 429-8567,[email protected]Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505,[email protected]

Frequently Asked Questions

What conference will INOVIO participate in?

INOVIO will participate in the World Federation of Hemophilia World Congress.

When will INOVIO present at the conference?

INOVIO's presentations are scheduled for April 22.

What topics will INOVIO present?

INOVIO will present on DPROT technology and FVIII expression in hemophilia A.

Where can I find INOVIO's presentation abstracts?

Abstracts will be available on INOVIO's website after the presentations.

ShareAdd on Google
Tags: INO Viatris Investor Conferences Healthcare INOVIO DNA medicines hemophilia A scientific conference DPROT technology
Last updated: Apr 1, 2026

Biotech snapshot

Cash runway
$37M liquidity · $6M/mo burn
~6 mo
High dilution risk
Lead asset
VGX-410Phase 2
Hepatitis C Virus Infection →